Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.

MLA

Xue, Feng, et al. “Safety and Activity of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing a Hyperactive Padua Factor IX Administered with Prophylactic Glucocorticoids in Patients with Haemophilia B: A Single-Centre, Single-Arm, Phase 1, Pilot Trial.” The Lancet. Haematology, vol. 9, no. 7, July 2022, pp. e504–13. EBSCOhost, https://doi.org/10.1016/S2352-3026(22)00113-2.

APA

Xue, F., Li, H., Wu, X., Liu, W., Zhang, F., Tang, D., Chen, Y., Wang, W., Chi, Y., Zheng, J., Du, Z., Jiang, W., Zhong, C., Wei, J., Zhu, P., Fu, R., Liu, X., Chen, L., Pei, X., … Zhang, L. (2022). Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. The Lancet. Haematology, 9(7), e504–e513. https://doi.org/10.1016/S2352-3026(22)00113-2

Chicago

Xue, Feng, Huiyuan Li, Xia Wu, Wei Liu, Feixu Zhang, Dingyue Tang, Yunfei Chen, et al. 2022. “Safety and Activity of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing a Hyperactive Padua Factor IX Administered with Prophylactic Glucocorticoids in Patients with Haemophilia B: A Single-Centre, Single-Arm, Phase 1, Pilot Trial.” The Lancet. Haematology 9 (7): e504–13. doi:10.1016/S2352-3026(22)00113-2.